" class="no-js "lang="en-US"> Matrivax Initiates Development of a Novel Pneumococcal Vaccine
Sunday, May 19, 2024

Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate

Vaccine development company Matrivax announces the start of its Phase 1 clinical study to assess the safety, tolerability, and immunogenicity of its lead pneumococcal disease vaccine candidate, MVX01.

Streptococcus pneumoniae is the primary bacterial cause of community-acquired pneumonia and meningitis, and a significant cause of otitis media, sinusitis, and bacteremia. Pneumococcal disease continues to be a major global public health concern causing greater than 1 million deaths worldwide annually, with a substantial proportion of fatalities among the elderly and immunocompromised, and in children populations less than 5 years old in Asian and African countries.

MVX01 is a fusion protein of two highly conserved protein antigens across Streptococcus pneumoniae bacterial serotypes: a genetically inactivated form of the virulence factor, pneumolysin toxin, and two epitopes from the cell surface protein, choline binding protein A.

“This Phase 1 study is an exciting milestone for Matrivax, and a major step forward in the development of a vaccine that has potential to be a technological breakthrough in vaccination options against pneumococcal disease,” said Enda Moran, Chief Executive Officer of Matrivax. “While there are effective vaccines currently available, they are very expensive to the end-user, and they don’t protect against all the bacterial serotypes that can cause disease. Our low-cost manufacturing platform and the prospect of a single-component, broad-coverage vaccine can translate directly into a much needed low-cost vaccine for pneumococcal disease.”

Kevin Killeen, Chief Scientific Officer of Matrivax, added, “Our preclinical data clearly demonstrate that MVX01 effectively immunizes and protects against a broad range of S. pneumoniae bacterial serotypes, including the serotypes covered by the leading commercial 20-valent conjugate vaccine. We’ve engineered the vaccine to present antigens to the vaccinee that are highly conserved across the >100 wild-type serotypes that cause pneumococcal disease. This vaccine candidate provides the real opportunity of a vaccine that can immunize against the broad spectrum of disease-causing strains. We are delighted to now start clinical development of the vaccine in human subjects with our clinical research partner, FHI Clinical.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more